Gusperimus: Immunological mechanism and clinical applications

Rheumatology (United Kingdom)

Volumn 53, Issue 10, 2014, Pages 1732-1741

  Perenyei, Miklos ^a   Jayne, David R W ^b   Floßmann, Oliver ^c  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

^c ROYAL BERKSHIRE HOSPITAL   (United Kingdom)

Author keywords

Deoxyspergualin; Glomerulonephritis; Gusperimus; Immune suppressant; Rejection; Systemic lupus erythematosus; Transplantation; Vasculitis

Indexed keywords

15 DEOXYSPERGUALIN;

ANCA ASSOCIATED VASCULITIS; CELLULAR IMMUNITY; DRUG ACTIVITY; DRUG MECHANISM; GLOMERULONEPHRITIS; GRAFT REJECTION; HUMAN; HUMORAL IMMUNITY; IMMUNE SYSTEM; NONHUMAN; PRIORITY JOURNAL; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 84928955394     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ket451     Document Type: Review

References (84)

1. Takeuchi T, Iinuma H, Kunimoto S et al. A new antitumor antibiotic, spergualin: isolation and antitumor activity. J Antibiot 1981;34:1619-21.
2. Umeda Y, Moriguchi M, Kuroda H et al. Synthesis and antitumor activity of spergualin analogue. I. Chemical modification of 7-guanidino-3-hydroxyacyl moiety. J Antibiot 1985;38:886-98.
3. Nemoto K, Hayashi M, Abe F et al. Immunosuppressive activities of 15-deoxyspergualin in animals. J Antibiot 1987;40:561-2.
4. Kaufman DB, Gores PF, Kelley S et al. 15-deoxyspergualin:immunotherapy in solid organ and cellular transplantation. Transplant Rev 1996;10:160-74.
5. Nadler SG, Tepper MA, Schacter B et al. Interaction of the immunosuppressant deoxyspergualin with a member of the Hsp70 family of heat shock proteins. Science 1992; 258:484-86.
6. Nadler SG, Dischino DD, Malacko AR et al. Identification of a binding site on Hsc70 for the immunosuppressant 15-deoxyspergualin. Biochem Biophys Res Commun 1998;253:176-80.
7. Nadeau K, Nadler SG, Saulnier M et al. Quantitation of the interaction of the immunosuppressant deoxyspergualin and analogs with Hsc70 and Hsp90. Biochemistry 1994; 33:2561-67.
8. Nadler SG, Eversole AC, Tepper MA et al. Elucidating the mechanism of action of the immunosuppressant 15-deoxyspergualin. Ther Drug Monit 1995;17:700-3.
9. Tepper MA, Nadler SG, Esselstyn JM et al. Deoxyspergualin inhibits k light chain expression in 70Z/3 pre-B cells by blocking lipopolysaccharide-induced NF-kB activation. J Immunol 1995;155:2427-36.
10. Sugawara A, Torigoe T, Tamura Y et al. Polyamine compound deoxyspergualin inhibits heat shock protein-induced activation of immature dendritic cells. Cell Stress Chaperones 2009;14:133-39.
11. Diegel ML, Nadler SG, Kiener PA. In vivo administration of 15-deoxyspergulin inhibits antigen-presenting cell stimulation of T cells and NF-kB activation. Int Immunopharmacol 2002;2:1451-64.
12. Kawada M, Masuda T, Ishizuka M et al. 15-Deoxyspergualin inhibits Akt kinase activation and phosphatidylcholine synthesis. J Biol Chem 2002;277:27765-71.
13. Ramya TN, Surolia N, Surolia A. 15-Deoxyspergualin inhibits eukaryotic protein synthesis through eIF2a phosphorylation. Biochem J 2007;401:411-20.
14. Nishimura K, Ohki Y, Fukuchi-Shimogori T et al. Inhibition of cell growth through inactivation of eukaryotic translation initiation factor 5A (eIF5A) by deoxyspergualin. Biochem J 2002;363:761-8.
15. Saini P, Eyler DE, Green R et al. Hypusine-containing protein eIF5A promotes translation elongation. Nature 2009;459:118-21.
16. Fujii H, Takada T, Nemoto K et al. In vitro immunosuppressive properties of spergualins to murine T cell response. J Antibiot 1989;42:788-94.
17. Holcombe H, Mellman I, Janeway CA et al. The immunosuppressive agent 15-deoxyspergualin functions by inhibiting cell cycle progression and cytokine production following naive T cell activation. J Immunol 2002;169:4982-9.
18. Kälsch AI, Schmitt WH, Breedijk A et al. In vivo effects of cyclic administration of 15-deoxyspergualin on leucocyte function in patients with Wegener's granulomatosis. Clin Exp Immunol 2006;146:455-62.
19. Borg AJ, Kumagai-Braesch M, Möller E. 15-Deoxyspergualin inhibits interleukin 6 production in in vitro stimulated human lymphocytes. Transpl Immunol 1996;4:133-43.
20. Nishimura K, Tokunaga T. Mechanism of action of 15-deoxyspergualin. I. Suppressive effect on the induction of alloreactive secondary cytotoxic T lymphocytes in vivo and in vitro. Immunology 1989;68:66-71.
21. Fujii H, Takada T, Nemoto K et al. Deoxyspergualin, a novel immunosuppressant, markedly inhibits human mixed lymphocyte reaction and cytotoxic T-lymphocyte activity in vitro. Int J Immunopharmacol 1992;14:731-7.
22. Odaka C, Toyoda E, Nemoto K. Immunosuppressant deoxyspergualin induces apoptotic cell death in dividing cells. Immunology 1998;95:370-6.
23. Fujii H, Takada T, Nemoto K et al. Deoxyspergualin directly suppresses antibody formation in vivo and in vitro. J Antibiot 1990;43:213-9.
24. Morikawa K, Oseko F, Morikawa S. The suppressive effect of deoxyspergualin on the differentiation of human B lymphocytes maturing into immunoglobulin-producing cells. Transplantation 1992;54:526-31.
25. Morikawa K, Nemoto K, Miyawaki T et al. Deoxyspergualin preferentially inhibits the growth and maturation of anti-CD40-activated surface IgD+ B lymphocytes. Clin Exp Immunol 1998;112:495-500.
26. Pai LH, FitzGerald DJ, Tepper M et al. Inhibition of antibody response to Pseudomonas exotoxin and an immunotoxin containing Pseudomonas exotoxin by 15-deoxyspergualin in mice. Cancer Res 1990;50:7750-3.
27. Sterbenz KG, Tepper MA. Effect of 15-deoxyspergualin on antibody secretion by specific isotypes producing B-cell hybridomas and myelomas. Transplant Proc 1994;26:3218-20.
28. Kerr PG, Nikolic-Paterson DJ, Lan HY et al. Deoxyspergualin suppresses local macrophage proliferation in rat renal allograft rejection. Transplantation 1994; 58:596-601.
29. Dickneite G, Schorlemmer HU, Sedlacek HH. Decrease of mononuclear phagocyte cell functions and prolongation of graft survival in experimental transplantation by (+/-)-15-deoxyspergualin. Int J Immunopharmacol 1987;9:559-65.
30. Hoeger PH, Tepper MA, Faith A et al. Immunosuppressant deoxyspergualin inhibits antigen processing in monocytes. J Immunol 1994;153:3908-16.
31. Takasu S, Sakagami K, Morisaki F et al. Immunosuppressive mechanism of 15-deoxyspergualin on sinusoidal lining cells in swine liver transplantation:suppression of MHC class II antigens and interleukin-1 production. J Surg Res 1991;51:165-9.
32. Nikolic-Paterson DJ, Tesch GH, Lan HY et al. Deoxyspergualin inhibits mesangial cell proliferation and major histocompatibility complex class II expression. J Am Soc Nephrol 1995;5:1895-902.
33. Hiratsuka M, Kuramochi H, Takahashi K et al. Cytostatic effect of deoxyspergualin on a murine leukemia cell line L1210. Jpn J Cancer Res 1991;82:1065-8.
34. Amemiya H, Suzuki S, Ota K et al. A novel rescue drug, 15-deoxyspergualin. First clinical trials for recurrent graft rejection in renal recipients. Transplantation 1990;49:337-43.
35. Jung DY, Lee HJ, Lee EN et al. Beneficial effects of simultaneous treatment with 15-deoxyspergualin and monoclonal antibodies to CD45RB and CD154 on murine islet transplantation recipients. Transplantation 2006;82:188-95.
36. Okubo M, Tamura K, Kamata K et al. 15-Deoxyspergualin ''rescue therapy'' for methylprednisolone-resistant rejection of renal transplants as compared with anti-T cell monoclonal antibody (OKT3). Transplantation 1993;55:505-8.
37. Amada N, Okazaki H, Sato T et al. Prophylactic use of deoxyspergualin improves long-term graft survival in living related renal transplant recipients transfused with donorspecific blood. Transplant Proc 2001;33:2256-7.
38. Amada N, Okazaki H, Sato T et al. Prophylactic deoxyspergualin treatment in living-related renal-transplant recipients transfused with donor-specific blood. Transplantation 2003;75:60-6.
39. Amada N, Okazaki H, Sato T et al. Deoxyspergualin prophylaxis with tacrolimus further improves long-term graft survival in living-related renal-transplant recipients transfused with donor-specific blood. Transplant Proc 2005;37:927-9.
40. Groth CG, Ohlman S, Ericzon BG et al. Deoxyspergualin for liver graft rejection. Lancet 1990; 336:626.
41. Katoh H, Ohkohchi N, Orii T et al. Effectiveness of 15-deoxyspergualin on steroid-resistant acute rejection in living related liver transplantation. Transplant Proc 1997; 29:553-4.
42. Nakanishi C, Kawagishi N, Sekiguchi S et al. Steroidresistant late acute rejection after a living donor liver transplantation: case report and review of the literature. Tohoku J Exp Med 2007;211:195-200.
43. Kawagishi N, Satoh K, Enomoto Y et al. Usage of deoxyspergualin on steroid-resistant acute rejection in living donor liver transplantation. Tohoku J Exp Med 2006;208:225-33.
44. Asiedu C, Goodwin K, Balgansuren G et al. Erratum (retracted article): Elevated T regulatory cells in long-term stable transplant tolerance in rhesus macaques induced by anti-CD3 immunotoxin and deoxyspergualin. J Immunol 2006; 177:2023.
45. Marchase RB. Retraction: Peritransplant tolerance induction in macaques: early events reflecting the unique synergy between immunotoxin and deoxyspergualin. Transplantation 2008; 86:482.
46. Kirk AD, Mannon RB, Kleiner DE et al. Results from a human renal allograft tolerance trial evaluating T-cell depletion with alemtuzumab combined with deoxyspergualin. Transplantation 2005;80:1051-9.
47. Gores PF, Najarian JS, Stephanian E et al. Insulin independence in type I diabetes after transplantation of unpurified islets from single donor with 15-deoxyspergualin. Lancet 1993;341:19-21.
48. Peritransplant Deoxyspergualin in Islet Transplantation in Type 1 Diabetes. ClinicalTrials.gov. Bethesda, MD, USA:National Library of Medicine. http://clinicaltrials.gov/ct2/show/NCT00434850NCT00434850 (4 August 2013, date last accessed).
49. Ablake M, Itoh M, Kaneko T et al. Short-term prophylaxis with deoxyspergualin prevents testicular autoimmunity in mice. Eur J Pharmacol 2002;450:209-12.
50. Nikolic-Paterson DJ, Kerr PG, Lan HY et al. Deoxyspergualin: a new immunosuppressive drug for the treatment of auto-immune disease. Nephron 1995;70:391-6.
51. Schorlemmer HU, Dickneite G. Preclinical studies with 15-deoxyspergualin in various animal models for autoimmune diseases. Ann N Y Acad Sci 1993;685:155-74.
52. Birck R, Newman M, Braun C et al. 15-Deoxyspergualin and cyclophosphamide, but not mycophenolate mofetil, prolong survival and attenuate renal disease in a murine model of ANCA-associated crescentic nephritis. Nephrol Dial Transplant 2006;21:58-63.
53. Tomizawa K, Nagao T, Kusunoki R et al. Reduction of MPO-ANCA epitopes in SCG/Kj mice by 15-deoxyspergualin treatment restricted by IgG2b associated with crescentic glomerulonephritis. Rheumatology 2010;49:1245-56.
54. Le Berre L, Bruneau S, Naulet J et al. Induction of T regulatory cells attenuates idiopathic nephrotic syndrome. J Am Soc Nephrol 2009;20:57-67.
55. Birck R, Warnatz K, Lorenz HM et al. 15-Deoxyspergualin in patients with refractory ANCA-associated systemic vasculitis: a six-month open-label trial to evaluate safety and efficacy. J Am Soc Nephrol 2003;14:440-7.
56. Flossmann O, Baslund B, Bruchfeld A et al. Deoxyspergualin in relapsing and refractory Wegener's granulomatosis. Ann Rheum Dis 2009;68:1125-30.
57. Trotti A, Colevas AD, Setser A et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003;13:176-81.
58. Schmitt WH, Birck R, Heinzel PA et al. Prolonged treatment of refractory Wegener's granulomatosis with 15-deoxyspergualin: an open study in seven patients. Nephrol Dial Transplant 2005;20:1083-92.
59. Flossmann O, Jayne DR. Long-term treatment of relapsing Wegener's granulomatosis with 15-deoxyspergualin. Rheumatology 2010;49:556-62.
60. Spanidin in Relapsing Granulomatosis with Polyangiitis (Wegener's granulomatosis)-SPARROW Study. ClinicalTrials.gov. Bethesda, MD, USA: National Library of Medicine. http://clinicaltrials.gov/ct2/show/NCT01446211 (4 August 2013, date last accessed); https://www.clini caltrialsregister.eu/ctr-search/trial/2011-001219-30/GB (4 August 2013, date last accessed).
61. British Society of Rheumatology. BSR Guidelines for the management of adults with ANCA associated vasculitis. http://www.rheumatology.org.uk/resources/guidelines/draft_guidelines_for_consultation/default.aspx (4 August 2013, date last accessed).
62. Hotta O, Furuta T, Chiba S et al. Effects of deoxyspergualin on proliferative glomerulonephritis. Am J Kidney Dis 1999;34:894-901.
63. Imai H, Hotta O, Yoshimura M et al. Deoxyspergualin, an immunosuppressant, in patients suffering from nephropathies with crescent formation: an open-label trial to evaluate safety and efficacy. Clin Exp Nephrol 2006;10:40-54.
64. Makino M, Fujiwara M, Aoyagi T et al. Immunosuppressive activities of deoxyspergualin. I. Effect of the long-term administration of the drug on the development of murine lupus. Immunopharmacology 1987;14:107-13.
65. Okubo M, Inoue K, Umetani N et al. Lupus nephropathy in New Zealand F1 hybrid mice treated by (-)15-deoxyspergualin. Kidney Int 1988;34:467-73.
66. Ito S, Ueno M, Arakawa M et al. Therapeutic effect of 15-deoxyspergualin on the progression of lupus nephritis in MRL mice. I. Immunopathological analyses. Clin Exp Immunol 1990;81:446-53.
67. Schorlemmer HU, Bartlett RR, Seiler FR. 15-Deoxyspergualin (15-DOS) has a curative effect on the development of SLE-like autoimmune disease in MRL/1 mice. Agents Actions 1991;34:151-5.
68. Lorenz HM, Grunke M, Wendler J et al. Safety of 15-deoxyspergualin in the treatment of glomerulonephritis associated with active systemic lupus erythematosus. Ann Rheum Dis 2005;64:1517-9.
69. Lorenz HM, Schmitt WH, Tesar V et al. Treatment of active lupus nephritis with the novel immunosuppressant 15-deoxyspergualin: an open-label dose escalation study. Arthritis Res Ther 2011;13:R36.
70. Schorlemmer HU, Dickneite G. Disease modifying activity of 15-deoxyspergualin on acute and chronic relapsing experimental allergic encephalomyelitis as models of multiple sclerosis (MS). Agents Actions 1991;34:156-60.
71. Wiendl H, Neuhaus O, Kappos L et al. Multiple sclerosis. Current review of failed and discontinued clinical trials of drug treatment. Nervenarzt 2000;71:597-610.
72. Hibasami H, Midorikawa Y, Gasaluck P et al. Bactericidal effect of 15-deoxyspergualin on Staphylococcus aureus. Chemotherapy 1991;37:202-5.
73. Hibasami H, Midorikawa Y, Gasaluck P et al. Growth inhibition of Candida by 15-deoxyspergualin, an immunosuppressive agent used in experimental organ transplantation. Lett Appl Microbiol 1992;14:81-3.
74. Midorikawa Y, Haque QM. 15-Deoxyspergualin, an immunosuppressive agent, used in organ transplantation showed suppressive effects on malarial parasites. Chemotherapy 1997;43:31-5.
75. Midorikawa Y, Haque QM, Nakazawa S. Inhibition of malaria-infected erythrocytes by deoxyspergualin: effect on in vitro growth of malarial cultures. Chemotherapy 1998;44:409-13.
76. Ramya TN, Surolia N, Surolia A. 15-Deoxyspergualin modulates Plasmodium falciparum heat shock protein function. Biochem Biophys Res Commun 2006;348:585-92.
77. Ramya TN, Karmodiya K, Surolia A et al. 15-deoxyspergualin primarily targets the trafficking of apicoplast proteins in Plasmodium falciparum. J Biol Chem 2007;282:6388-97.
78. Banerjee T, Singh RR, Gupta S et al. 15-Deoxyspergualin hinders physical interaction between basic residues of transit peptide in PfENR and Hsp70-1. IUBMB Life 2012; 64:99-107.
79. Lee J, Kim MS, Kim EY et al. 15-deoxyspergualin prevents mucosal injury by inhibiting production of TNF-a and down-regulating expression of MD-1 in a murine model of TNBS-induced colitis. Int Immunopharmacol 2007;7:1003-12.
80. Cicho G, Strauss M. Transient immunosuppression with 15-deoxyspergualin prolongs reporter gene expression and reduces humoral immune response after adenoviral gene transfer. Gene Ther 1998;5:85-90.
81. Kaplan JM, Smith AE. Transient immunosuppression with deoxyspergualin improves longevity of transgene expression and ability to readminister adenoviral vector to the mouse lung. Hum Gene Ther 1997;8:1095-104.
82. Dhingra K, Fritsche H, Murray JL et al. Phase I clinical and pharmacological study of suppression of human antimouse antibody response to monoclonal antibody L6 by deoxyspergualin. Cancer Res 1995;55:3060-7.
83. Fox EJ, Vartanian TK, Zamvil SS. The immunogenicity of disease-modifying therapies for multiple sclerosis: clinical implications for neurologists. Neurologist 2007;13:355-62.
84. Flossmann O, Jayne DRW. Maintaining remission in a patient with vasculitis. Nat Clin Pract Rheumatol 2008;4:499-504.